Literature DB >> 3790170

3-Deazaneplanocin A: a new inhibitor of S-adenosylhomocysteine synthesis and its effects in human colon carcinoma cells.

R I Glazer, M C Knode, C K Tseng, D R Haines, V E Marquez.   

Abstract

The mechanism of action of the cyclopentenyl analogue of 3-deazaadenosine (3-deazaneplanocin A or c3Nep) was investigated in the human colon carcinoma cell line HT-29. Upon exposure of cells for 24 hr to 3-deazaneplanocin A (c3Nep), neplanocin A (Nep) or 3-deazaaristeromycin (c3Ari), significant toxicity was noted only for Nep, wherein an 87% reduction in viability was produced at a 100 microM concentration. c3Nep and c3Ari at 100 microM reduced viability by 34 and 21%, respectively. Intracellular levels of S-adenosylhomocysteine (AdoHcy) were elevated by a 24-hr exposure to 100 microM c3Nep, Nep and c3Ari and were 120, 75 and 25 pmoles/10(6) cells respectively. Only Nep was metabolized to an S-adenosylmethionine-like metabolite, and its formation was dose-related to its cytotoxicity. The t1/2 for the disappearance of elevated levels of AdoHcy following drug removal was 1.6 to 2.5 hr for all drugs. rRNA and tRNA methylation was inhibited significantly by Nep, but c3Nep and c3Ari inhibited tRNA methylation but not rRNA methylation to a lesser degree. These results demonstrate that c3Nep is a potent inhibitor of AdoHcy synthesis with a low degree of cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3790170     DOI: 10.1016/0006-2952(86)90774-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  23 in total

1.  Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5'-nor derivatives.

Authors:  E De Clercq; M Cools; J Balzarini; V E Marquez; D R Borcherding; R T Borchardt; J C Drach; S Kitaoka; T Konno
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 2.  Epigenetic cancer prevention mechanisms in skin cancer.

Authors:  Kamalika Saha; Thomas J Hornyak; Richard L Eckert
Journal:  AAPS J       Date:  2013-08-01       Impact factor: 4.009

3.  Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.

Authors:  Amir Avan; Francesco Crea; Elisa Paolicchi; Niccola Funel; Elena Galvani; Victor E Marquez; Richard J Honeywell; Romano Danesi; Godefridus J Peters; Elisa Giovannetti
Journal:  Mol Cancer Ther       Date:  2012-05-23       Impact factor: 6.261

4.  9-(trans-2',trans-3'-Dihydroxycyclopent-4'-enyl)-adenine and -3-deazaadenine: analogs of neplanocin A which retain potent antiviral activity but exhibit reduced cytotoxicity.

Authors:  M Hasobe; J G McKee; D R Borcherding; R T Borchardt
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

5.  Survival of skin cancer stem cells requires the Ezh2 polycomb group protein.

Authors:  Gautam Adhikary; Daniel Grun; Sivaprakasam Balasubramanian; Candace Kerr; Jennifer M Huang; Richard L Eckert
Journal:  Carcinogenesis       Date:  2015-05-12       Impact factor: 4.944

6.  (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells.

Authors:  Subhasree Roy Choudhury; Sivaprakasam Balasubramanian; Yap Ching Chew; Bingshe Han; Victor E Marquez; Richard L Eckert
Journal:  Carcinogenesis       Date:  2011-07-27       Impact factor: 4.944

7.  Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells.

Authors:  Yannick D Benoit; Mavee S Witherspoon; Kristian B Laursen; Amel Guezguez; Marco Beauséjour; Jean-Francois Beaulieu; Steven M Lipkin; Lorraine J Gudas
Journal:  Exp Cell Res       Date:  2013-04-12       Impact factor: 3.905

8.  Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.

Authors:  Feng Sun; Eli Chan; Zhenlong Wu; Xiaojing Yang; Victor E Marquez; Qiang Yu
Journal:  Mol Cancer Ther       Date:  2009-12       Impact factor: 6.261

9.  Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer.

Authors:  Deborah L Burkhart; Katherine L Morel; Kristine M Wadosky; David P Labbé; Phillip M Galbo; Zafardjan Dalimov; Bo Xu; Massimo Loda; Leigh Ellis
Journal:  Cancer Prev Res (Phila)       Date:  2020-09-11

10.  Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells.

Authors:  Yannick D Benoit; Kristian B Laursen; Mavee S Witherspoon; Steven M Lipkin; Lorraine J Gudas
Journal:  J Cell Physiol       Date:  2013-04       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.